Kawasaki disease

Current Opinion in Pediatrics

Volumn 16, Issue 5, 2004, Pages 508-514

  Newburger, Jane W ^a   Fulton, David R ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Intravenous immune globulin therapy; Kawasaki disease

Indexed keywords

ABCIXIMAB; CORTICOSTEROID; IMMUNOGLOBULIN; INFLIXIMAB;

ACUTE DISEASE; CHILD; CONJUNCTIVITIS; CORONARY ARTERY ANEURYSM; DRUG EFFICACY; ERYTHEMA; FEVER; HEART DISEASE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; LYMPHADENOPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PREVALENCE; PRIORITY JOURNAL; RASH; REVIEW; RHEUMATIC FEVER; SUDDEN DEATH; TREATMENT INDICATION; UNITED STATES; VASCULITIS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ASPIRIN; CATHETER ABLATION; CHILD; CORONARY ARTERY BYPASS; CORONARY VESSEL ANOMALIES; CORONARY VESSELS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PROGNOSIS;

EID: 4644333752     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000137796.23813.64     Document Type: Review

References (92)

1. Kawasaki T: Acute febrile mucocutaneous lymph node syndrome: clinical observations of 50 cases. Japan J Allergology 1967, 16:178.
2. Yanagawa H, Nakamura Y, Yashiro M, et al.: Incidence survey of Kawasaki disease in 1997 and 1998 in Japan. Pediatrics 2001, 107:E33.
3. Holman RC, Curns AT, Belay ED, et al.: Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics 2003, 112:495-501. Estimates the incidence and describes the epidemiologic characteristics of Kawasaki disease among children in the United States using hospital discharge data.
4. Chang RK: The incidence of Kawasaki disease in the United States did not increase between 1988 and 1997. Pediatrics 2003, 111:1124-1125.
5. Stockheim JA, Innocentini N, Shulman ST: Kawasaki disease in older children and adolescents. J Pediatr 2000, 137:250-252.
6. Chang RK: Hospitalizations for Kawasaki disease among children in the United States, 1988-1997. Pediatrics 2002, 109:e87.
7. Momenah T, Sanatani S, Potts J, et al.: Kawasaki disease in the older child. Pediatrics 1998, 102:e7.
8. Yanagawa H, Nakamura Y, Yashiro M, et al.: Results of the nationwide epidemiologic survey of Kawasaki disease in 1995 and 1996 in Japan. Pediatrics 1998, 102:1-5.
9. Fujita Y, Nakamura Y, Sakata K, et al.: Kawasaki disease in families. Pediatrics 1989, 84:666-669.
10. Harada F, Sada M, Kamiya T, et al.: Genetic analysis of Kawasaki syndrome. Am J Hum Genet 1986, 39:537-539.
11. Uehara R, Yashiro M, Nakamura Y, et al.: Kawasaki disease in parents and children. Acta Paediatr 2003, 92:694-697. This study suggests a genetic predisposition to Kawasaki disease.
12. Fujiwara H, Hamashima Y: Pathology of the heart in Kawasaki disease. Pediatrics 1978, 61:100-107.
13. Burns JC, Shike H, Gordon JB, et al.: Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol 1996, 28:253-257.
14. Abe J, Kotzin BL, Jujo K, et al.: Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci USA 1992, 89:4066-4070.
15. Yamashiro Y, Nagata S, Oguchi S, et al.: Selective increase of VB2+ T cells in the small intestinal mucosa in Kawasaki disease. Pediatr Res 1996, 39:264-266.
16. Leung DWM, Giorno RC, Kazemi LV, et al.: Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J Immunol 1995, 155:5018-5021.
17. Leung DYM: Superantigens related to Kawasaki syndrome. Springer Semin Immunopathol 1996, 17:385-396.
18. Brogan PA, Shah V, Klein N, et al.: Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury. Arthritis Rheum 2004, 50:589-597.
19. Leung DY, Meissner HC, Shulman ST, et al.: Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. J Pediatr 2002, 140:742-746.
20. Gupta-Malhotra M, Viteri-Jackson A, Thomas W, et al.: Antibodies to highly conserved peptide sequence of staphylococcal and streptococcal superantigens in Kawasaki disease. Exp Mol Pathol 2004, 76:117-121. This study showed that children with Kawasaki disease before IVIG treatment were indistinguishable from control children in their antibody production to staphylococcal and streptococcal toxins.
21. Rowley AH, Eckerley CA, Jack HM, et al.: IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997, 159:5946-5955.
22. Rowley AH, Shulman ST, Spike BT, et al.: Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001, 166:1334-1343.
23. Rowley AH, Shulman ST, Mask CA, et al.: IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis 2000, 182:1183-1191.
24. Shulman ST, Rowley AH: Advances in Kawasaki disease. Eur J Pediatr 2004, Mar 23 (Epub ahead of print).
25. Brown TJ, Crawford SE, Cornwall ML, et al.: CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 2001, 184:940-943.
26. Gavin PJ, Crawford SE, Shulman ST, et al.: Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 2003, 23:576-581.
27. Dajani AS, Taubert KA, Gerber MA, et al.: Diagnosis and therapy of Kawasaki disease in children. Circulation 1993, 87:1776-1780.
28. Witt MT, Minich LA, Bohnsack JF, et al.: Kawasaki disease: more patients are being diagnosed who do not meet American Heart Association criteria. Pediatrics 1999, 104:e10.
29. Joffe A: Atypical and complicated Kawasaki disease in infants: do we need criteria? West J Med 1995, 162:322-327.
30. Tseng CF, Fu YC, Fu LS, et al.: Clinical spectrum of Kawasaki disease in infants. Zhonghua Yi Xue Za Zhi (Tapei) 2001, 64:168-173.
31. Durongpisitkul K, Gururaj VJ, Park JM, et al.: The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995, 96:1057-1061.
32. Furusho K, Kamiya T, Nakano H, et al.: High-dose intravenous gamma globulin for Kawasaki disease. Lancet 1984, 2:1055-1058.
33. Newburger JW, Takahashi M, Burns JC, et al.: The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986, 315:341-347.
34. Terai M, Shulman ST: Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997, 131:888-893.
35. Marasini M, Pongiglione G, Gazzolo D, et al.: Late intravenous gamma globulin treatment in infants and children with Kawasaki disease and coronary artery abnormalities. Am J Cardiol 1991, 68:796-797.
36. Muta H, Ishii M, Egami K: Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 2004, 144:496-499. This large study demonstrates that treatment with IVIG before day 5 of illness does not result in a lower likelihood of coronary disease but is associated with a greater likelihood of IVIG retreatment.
37. Fong NC, Hui YW, Li CK, et al.: Evaluation of the efficacy of treatment of Kawasaki disease before day 5 of illness. Pediatr Cardiol 2004, 25:31-34. This case-control study also showed no benefit to very early treatment with IVIG.
38. Dajani AS, Taubert KA, Takahashi M, et al.: Guidelines for long-term management of patients with Kawasaki disease report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1994, 89:916-922.
39. Kato H, Koike S, Yokoyama T: Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979, 63:175-179.
40. Kijima Y, Kamiya T, Suzuki A, et al.: A trial procedure to prevent aneurysm formation of the coronary arteries by steroid pulse therapy in Kawasaki disease. Jpn Circ J 1982, 46:1239-1242.
41. Nonaka Z, Maekawa K, Okabe T, et al.: Randomized controlled study of intravenous prednisolone and gamma globulin treatment in 100 cases with Kawasaki disease. Proceedings of the Fifth International Symposium on Kawasaki Disease 1995;328-331.
42. Shinohara M, Sone K, Tomomasa T, et al.: Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 1999, 135:465-469.
43. Sundel RP, Baker AL, Fulton DR, et al.: Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003, 142:611-616. This pilot, open-label trial of primary treatment of pulse steroids in addition to IVIG and aspirin showed shorter duration of fever and hospitalization in children treated with steroids.
44. Jibiki T, Terai M, Kurosaki T, et al.: Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease. Eur J Pediatr 2004, 163:229-233.
45. Okada Y, Shinohara M, Kobayashi T, et al.: Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr 2003, 143:363-367.
46. Al Mayouf SM: The use of corticosteroid therapy in refractory Kawasaki patients. Clin Rheumatol 2004, 23:11-13.
47. Hung JJ, Chiu CH: Pulse methylprednisolone therapy in the treatment of immune globulin-resistant Kawasaki disease: case report and review of the literature. Ann Trap Paediatr 2004, 24:89-93.
48. Hashino K, Ishii M, Iemura M, et al.: Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001, 43:211-217.
49. Imagawa T, Mori M, Miyamae T, et al.: Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004, 163:263-264.
50. Williams RV, Wilke VM, Tani LY, et al. : Does abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatr 2002, 109:E4.
51. Weiss JE, Eberhard BA, Chowdhury D, et al.: Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004, 31:808-810.
52. Kato H, Sugimura T, Akagi T, et al.: Long-term consequences of Kawasaki disease: a 10- to 21 -year follow-up study of 594 patients. Circulation 1996, 94:1379-1385.
53. Beiser AS, Takahashi M, Baker AL, et al.: A predictive instrument for coronary artery aneurysms in Kawasaki disease. Am J Cardiol 1998, 81:1116-1120.
54. Harada K: Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991, 33:805-810.
55. Nakamura Y, Yashiro M, Uehara R, et al.: Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 2004, 46:33-38.
56. Research Committee on Kawasaki Disease: Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. 1984. Tokyo: Ministry of Health and Welfare.
57. de Zorzi A, Colan SD, Gauvreau K, et al.: Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998, 133:254-258.
58. Kondo C, Hiroe M, Nakanishi T, et al.: Detection of coronary artery stenosis in children with Kawasaki disease. Circulation 1989, 80:615-624.
59. Jan SL, Hwang B, Fu YC, et al.: Comparison of 201TI SPET and treadmill exercise testing in patients with Kawasaki disease. Nucl Med Commun 2000, 21:431-435.
60. Pahl E, Sehgal R, Chrystof D, et al.: Feasibility of exercise stress echocardiography for the follow-up of children with coronary involvement secondary to Kawasaki disease. Circulation 1995, 91:122-128.
61. Henein MY, Dinarevic S, O'Sullivan CA, et al.: Exercise echocardiography in children with Kawasaki disease: ventricular long axis is selectively abnormal. Am J Cardiol 1998, 81:1356-1359.
62. Noto N, Ayusawa M, Karasawa K, et al.: Dobutamine stress echocardiography for detection of coronary artery stenosis in children with Kawasaki disease. J Am Coll Cardiol 1996, 27:1251-1256.
63. Kimball TR, Witt SA, Daniels SR: Dobutamine stress echocardiography in the assessment of suspected myocardial ischemia in children and young adults. Am J Cardiol 1997, 79:380-384.
64. Bezold LI, Lewin MB, Vick GW III, et al.: Update on new technologies in pediatric echocardiography. Tex Heart Inst J 1997, 24:278-286.
65. Muhling O, Jerosch-Herold M, Nabauer M, et al.: Assessment of ischemic heart disease using magnetic resonance first-pass perfusion imaging. Herz 2003, 28:82-89.
66. Kaul S, Ito H: Microvasculature in acute myocardial ischemia: Part I. Evolving concepts in pathophysiology, diagnosis, and treatment. Circulation 2004, 109:146-149.
67. Zilberman MV, Witt SA, Kimball TR: Is there a role for intravenous transpulmonary contrast imaging in pediatric stress echocardiography? J Am Soc Echocardiogr 2003, 16:9-14.
68. Greil GF, Stuber M, Botnar RM, et al.: Coronary magnetic resonance angiography in adolescents and young adults with Kawasaki disease. Circulation 2002, 105:908-911.
69. Danias PG, Stuber M, Botnar RM, et al.: Coronary MR angiography clinical applications and potential for Imaging coronary artery disease. Magn Reson Imaging Clin North Am 2003, 11:81-99.
70. Mavrogeni S, Papadopoulos G, Douskou M, et al.: Magnetic resonance angiography is equivalent to x-ray coronary angiography for the evaluation of coronary arteries in Kawasaki disease. J Am Coll Cardiol 2004, 43:649-652.
71. Sohn S, Kim HS, Lee SW: Multidetector row computed tomography for follow-up of patients with coronary artery aneurysms due to Kawasaki disease. Pediatr Cardiol 2004, 25:35-39.
72. Schmidt WA: Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep 2004, 6:203-211.
73. Guidelines for treatment and management of cardiovascular in Kawasaki disease. Subcommittee of Cardiovascular Sequelae, Subcommittee of Surgical Treatment, Kawasaki Disease Research Committee. Heart Vessels 1987, 3:50-54.
74. Kitamura S, Kameda Y, Seki T, et al.: Long-term outcome of myocardial revascularization in patients with Kawasaki coronary artery disease. J Thorac Cardiovasc Surg 1994, 107:663-674.
75. Kitamura S: The role of coronary bypass operation on children with Kawasaki disease. Coron Artery Dis 2002, 13:437-447.
76. Ogawa S, Ohkubo T, Fukazawa R: Estimation of myocardial hemodynamics before and after intervention in children with Kawasaki disease. J Am Coll Cardiol 2004, 43:653-661. Myocardial fractional flow reserve and coronary flow reserve were measured in children with coronary stenoses before and after intervention with balloon angioplasties and coronary artery bypass procedures. These measures returned to normal after coronary interventions.
77. Ishii M, Ueno T, Ikeda H, et al.: Sequential follow-up results of catheter intervention for coronary artery lesions after Kawasaki disease: quantitative coronary artery angiography and intravascular ultrasound imaging study. Circulation 2002, 105:3004-3010.
78. Ishii M, Ueno T, Akagi T, et al.: Guidelines for catheter intervention in coronary artery lesion in Kawasaki disease. Pediatr Int 2001, 43:558-562.
79. Takahashi M, Mason W, Lewis AB: Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation 1987, 75:387-394.
80. Kamiya T, Suzuki A, Ono Y, et al.: Angiographic follow-up study of coronary artery lesion in the cases with a history of Kawasaki disease, with a focus on the follow-up more than ten years after the onset of the disease. In: Kato H, editor. Kawasaki Disease. Proceedings of the 5th International Kawasaki Disease Symposium, Fukuoka, Japan, May 22-25, 1995, The Netherlands: Elsevier Science B.V., 1995:569-573.
81. Tsuda E, Kamiya T, Ono Y, et al,: Incidence of stenotic lesions predicted by acute phase changes in coronary arterial diameter during Kawasaki disease. Pediatr Cardiol 2004 May 12 (Epub ahead of print). These authors demonstrate that the incidence of coronary artery stenosis in patients with aneurysms increases with duration from disease onset. By 15 years after Kawasaki disease, stenotic lesions had developed in 74% of giant aneurysms (≥8 mm) and 58% of medium aneurysms (6-8 mm).
82. Kurisu Y, Azumi T, Sugahara T, et al.: Variation in coronary arterial dimension (distensible abnormality) after disappearing aneurysm in Kawasaki disease. Am Heart J 1987, 114:532-538.
83. Matsumura K, Okuda Y, Ito T, et al.: Coronary angiography of Kawasaki disease with the coronary vasodilator dipyridamole: assessment of distensibility of affected coronary arterial wall. Angiology 1988, 39:141-147.
84. Sugimura T, Kato H, Inoue O, et al.: Vasodilatory response of the coronary arteries after Kawasaki disease: evaluation by intracoronary injection of isosorbide dinitrate. J Pediatr 1992, 121:684-688.
85. Iemura M, Ishii M, Sugimura T, et al.: Long term consequences of regressed coronary aneurysms after Kawasaki disease: vascular wall morphology and function. Heart 2000, 83:307-311.
86. Tsuda E, Kamiya T, Kimura K: Coronary artery dilatation exceeding 4.0 mm during acute Kawasaki disease predicts a high probability of subsequent late intima-medial thickening. Pediatr Cardiol 2002, 23:9-14.
87. Hauser M, Bengel F, Kuehn A: Myocardial blood flow and coronary flow reserve in children with "normal" epicardial coronary arteries after the onset of Kawasaki disease assessed by positron emission tomography. Pediatr Cardiol 2004, 25:108-112. In children with regressed coronary aneurysms, vasoreactivity of coronary arteries was impaired, suggesting that there may be residual damage of the coronary arteries that may be a risk factor for atherosclerosis in adulthood.
88. Cheung YF, Yung TC, Tam SC: Novel and traditional cardiovascular risk factors in children after Kawasaki disease: implications for premature atherosclerosis. J Am Coll Cardiol 2004, 43:120-124. These authors demonstrate an adverse risk profile in patients with Kawasaki disease, including those in whom coronary artery abnormalities were never detected.
89. Dhillon R, Clarkson P, Donald AE, et al.: Endothelial dysfunction late after Kawasaki disease. Circulation 1996, 94:2103-2106.
90. Mitani Y, Okuda Y, Shimpo H, et al.: Impaired endothelial function in epicardial coronary arteries after Kawasaki disease. Circulation 1997, 96:454-461.
91. Yamakawa R, Ishii M, Sugimura T, et al.: Coronary endothelial dysfunction after Kawasaki disease: evaluation by intracoronary injection of acetylcholine. J Am Coll Cardiol 1998, 31:1074-1080.
92. Muzik O, Paridon SM, Singh TP, et al.: Quantification of myocardial blood flow and flow reserve in children with a history of Kawasaki disease and normal coronary arteries using positron emission tomography. J Am Coll Cardiol 1996, 28:757-762.